[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570861":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":55,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":20,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":20,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Feasibility","EXPERIMENTAL","Patients treated with PULSAR will undergo treatment over a total duration of 2-5 months with 3-4 weeks between each fraction. PULSAR treatments completed within 6 months will be acceptable if treatment breaks are required. In the event of a complete response between fractions, remaining fractions will be withheld at the discretion of the treating physician. Treatment may also be terminated for selected grade 3 or higher AEs. Treatment may also be terminated for regional or systemic progression detected during the PULSAR treatment interval.",[13],"Radiation: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)","Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases",[9],null,[22],{"name":23,"affiliation":5,"role":24},"KENNETH WESTOVER, MD, PhD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"SARAH NEUFELD, MS, MBA","CONTACT","214-645-8525","sarah.hardee@UTSouthwestern.edu",{"name":23,"role":28,"phone":32,"phoneExt":20,"email":33},"214 645 0323","Kenneth.Westover@UTSouthwestern.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Dallas","Texas","75390","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-96.80667,32.78306,{"lat":46,"lon":45},[49,52,54],{"name":50,"role":28,"phone":51,"phoneExt":20,"email":20},"SARAH NEUFELD SUPERVISOR OF CLINICAL RESEARCH, MS, MBA","214 648 1836",{"name":20,"role":28,"phone":20,"phoneExt":20,"email":53},"Sarah.Hardee@UTSouthwestern.edu",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Kenneth Westover","Associate Professor",[59],{"name":60,"class":61},"Elekta Limited","INDUSTRY","100570861","early-phase-1-feasibility-study-of-personalized-ultra-fractionated-stereotactic-ablative-radiotherapy-pulsar-for-cancers-of-the-central-lung-100570861",false,"NCT06712745","Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung","Inclusion Criteria:\n\n1. Age ≥ 18 years of age.\n2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically judged as related to the biopsied site.\n3. Stage: Tumor (ITV) 1.5 - 5 cm in maximum diameter.\n4. Tumor entirely within the 2 cm \"central zone\" or within 1 cm of the mediastinum, esophagus or proximal bronchial tree by investigator assessment.\n5. Zubrod\u002FECOG Performance Status 0-2 within 30 days prior to registration.\n6. Ability to tolerate MRI.\n7. All men, as well as women of child-bearing potential\\* must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of consent, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nNote: A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.\n2. Plans for the patient to receive other local therapy in lung (including standard fractionated radiotherapy and\u002For surgery) while on this study, except at disease progression.\n3. Females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n4. Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.","ALL","18 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"EARLY_PHASE1","The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.",[78,79],"Cancer, Lung","Metastasis",[81,82,83,84,85,86,87],"lung","central lumg","cancer","metastasis","PULSAR","non small cell lung cancer","NSCLC","2026-06-24",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2025-09-19",{"date":95,"type":72},"2028-12-30",{"name":5,"class":6},1]